The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation by Selby, PJ et al.
B( 9 The Macmillan Press Ltd., 1989
The prophylactic role of intravenous and long-term oral acyclovir after
allogeneic bone marrow transplantation
P.J. Selby', R.L. Powles', D. Easton2, T.J. Perren', K. Stolle', B. Jameson', A.P. Fiddian3,
Y. Tryhorn4 & H. Stern4
Sections of 1Medicine and 2 Epidemiology, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton,
Surrey SM2 5PT, UK; 3Wellcome Research Laboratories, Langley Court, Beckenham, Kent, UK; and 4Department of
Virology, St Georges Hospital Medical School, Tooting, London, SW17, UK.
Summary Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg 1t.d.s. for
23 days followed by oral acyclovir 800mg 6-hourly for 6 months or matching placebos after allogeneic bone
marrow transplantation. Herpes simplex and varicella zoster virus infections were significantly reduced during
the period of administration of acyclovir. No reduction in cytomegalovirus infection was demonstrated. The
drug was not toxic.
The introduction of acyclovir into clinical practice was a
useful development in the management of herpesvirus
infections (Selby et al., 1979). The drug has been proved to
be a highly effective treatment for herpes simplex (HSV) and
varicella zoster virus (VZV) infections both in immune
compromised and immune competent patients (Meyers et al.,
1982; Balfour et al., 1983; Prober et al., 1982; reviewed by
Fiddian & Grant, 1985; Prentice & Hann, 1985; Strauss,
1985; Gore & Selby, 1987). The efficacy and lack of toxicity
of acyclovir has led to its use to prevent reactivation of
herpesvirus infections. It is effective in the prophylaxis of
HSV reactivation both in the immune competent patient
with, for instance, recurrent genital herpes simplex and in the
immune compromised patient, after, for instance, allogeneic
bone marrow transplantation (Saral et al., 1981; Gluckman
et al., 1983; Wade, 1984; Fiddian & Grant, 1985; Prentice &
Hann, 1985; Straus, 1985; Gore & Selby, 1987). However,
information about the prophylaxis of VZV infection is much
less complete.
The concentrations of acyclovir that are required to inhibit
VZV in vitro are much higher than those required to inhibit
HSV. This observation, together with the limited absorption
of acyclovir when given by the oral route (Brigden &
Whiteman, 1985), led to doubt about the effectiveness of
acyclovir for the oral treatment or prophylaxis of VZV.
However, it has been shown that oral acyclovir in high doses
is effective in shortening the duration of VZV infections in
immune competent patients (Peterslund, 1985; McKendrick
et al., 1986).
Reactivation of both HSV and VZV after bone marrow
transplantation are a common source of morbidity. Up to
70% of patients who are seropositive for HSV infection
develop reactivations and 40% of patients get herpes zoster
or varicella (Saral et al., 1981; Locksley et al., 1985).
However, evidence that long-term oral acyclovir will prevent
the development of VZV was inconclusive. We have
therefore carried out a prospective randomised double blind
trial of intravenous acyclovir given for 23 days followed by
oral acyclovir for 6 months in patients following allogeneic
bone marrow transplantation.
Patients and methods
All patients with a diagnosis of acute leukaemia who were
referred to the Acute Leukaemia Unit at the Royal Marsden
Hospital between September 1983 and May 1986 for
matched or one haplotype mismatched allogeneic bone
marrow transplantation were eligible for this trial. The
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programme was approved by the Ethical Committee of the
Royal Marsden Hospital. Informed consent was obtained.
Patients were randomised by double blind to receive either
acyclovir or a matching placebo. A minimisation method
was used to ensure a balance of patients with matched or
mismatched transplantation, herpes simplex virus sero-
positivity in the two groups (Freedman & White, 1976).
Acyclovir or placebo was administered to adults at a dose
of 5mg kg-1 in 100 ml of normal saline infused over 1 h,
given 8-hourly starting on the day before transplantation
and continuing for 23 days. At that point adults received
800mg tablets 6-hourly for 6 months. Children less than 12
years of age received 250 mgm- 2 acyclovir intravenously
followed by 400mg orally 6-hourly. Patients were prepared
for transplantation by treatment with intravenous cyclo-
phosphamide 1.8gm-2 daily for 2 days or with melphalan
lOmgm-2 intravenously and both of these drug treatments
were followed by 10-11.5 Gy total body irradiation in a
single dose. Prophylaxis against graft versus host disease was
given with oral cyclosporin A 8mg kg- 1 day 1. All patients
were nursed in protective isolation cubicles.
Pre-transplant assessments included a careful history of
previous HSV or VZV infection and of any recent contact
with such infections. Pre-transplant sera were analysed for
IgG antibodies against VZV, HSV and CMV. During the
period of transplantation patients were routinely clinically
examined twice weekly for evidence of virus infection and
the viral serological tests were repeated weekly in addition to
urine and buffy coat cultures for herpesviruses. Throat
washings and mouth swabs for virus culture were taken
weekly or when clinically indicated. After discharge both
serological and viral culture tests were repeated at each clinic
visit for one year post-transplant.
The criteria for a diagnosis of VZV were a typical clinical
picture confirmed virus isolation when appropriate. HSV
infection was diagnosed by viral culture. Cytomegalovirus
(CMV) infection was diagnosed by viral culture or by early
antigen detection in tissue culture.
When a patient developed HSV or VZV infection, the trial
regimen was discontinued without breaking the code and
commercially available acyclovir was substituted in a
conventional dose for 7 days. At the end of this treatment
the trial acyclovir or placebo was restarted. Two infections
with herpes simplex virus was felt to indicate long-term use
of open acyclovir and this was instigated. In the case of
suspected acyclovir toxicity the trial drug was stopped.
Statistical analysis
The principal analyses were of the time to first HSV, VZV
and CMV infections; the period of risk was considered to
start on day 5. Infections occurring in the first 4 days after
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transplantation were excluded from the analysis because it
seemed likely that these had started before the transplant.
Time-to-event curves were analysed for HSV infection, CMV
infection, haematological recovery and the development of
abnormal renal function. In these curves, the cumulative
probability of the end-point is plotted against time from
transplant and patients are censored at the point of follow-
up or at death from other causes.
Differences between acyclovir and placebo arms were
tested by log rank tests in each case. Because the intention
was to treat each patient for 6 months, the analysis has been
subdivided into periods of risk up to 6 months and beyond 6
months.
Results
Forty-two patients were randomised to receive intravenous
followed by oral acyclovir and 40 patients to receive the
matching placebos. Table I shows the patient characteristics.
In general the groups were well balanced according to
important prognostic variables. An excess of patients who
were seropositive for VZV and CMV is seen in the acyclovir
treatment arm of the trial.
All patients were followed for at least one year beyond the
time of transplantation and follow-up was completed in May
1987.
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Figure 1 Cumulative probability of herpes simplex virus
infection in patients receiving acyclovir (solid line) or placebo
(dotted line).
Prophylactic effect
Time-to-event curves for virological evidence of HSV
infection, clincial evidence of VZV infection and virological
evidence of CMV infection are shown in Figures 1-3. Log-
rank analysis of these curves is given in Table II.
Herpes simplex virus (HSV) A highly statistically significant
reduction in HSV infection during the period of
administration of acyclovir is seen. When acyclovir was
stopped at 6 months, reactivations quickly ensued in four
patients but there was a statistically significant overall
reduction in HSV infections for the whole period of
observation to one year.
Table I Summary of baseline characteristics of acyclovir and
placebo treated patients
Acyclovir
(number of patients)
Sex
Male
Female
Age (years)
<10
10-19
20-29
30-39
>a40
Matching
Match
Mismatch
Diagnosis
AML
ALL
CGL
T-Cell
NHL
Other
Initial seropositivity
HSV + ve
-ve
VZE + ve
-ve
CMV +ve
-ve
20
22
2
14
16
8
2
36
6
29
7
4
1
1
29
13
24
18
22
20
Placebo
(number of patients)
23
17
2
6
17
13
1
33
7
28
6
4
0
25
15
15
25
13
27
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Figure 2 Cumulative probability of varicella zoster virus
infection in patients receiving acyclovir (solid line) or placebo
(dotted line).
Varicella zoster virus (VZV) There was complete and
highly significant abolition of VZV infection during the
period of administration of acyclovir. When acyclovir was
discontinued at 6 months infections were seen quickly so
that there was no overall reduction in VZV infection over
the whole observation period of one year.
Cytomegalovirus There was no overall reduction in the
occurrence of CMV infection during the administration of
acyclovir at the doses used in this study. When the sub-
groups of CMV seropositive and seronegative patients were
analysed separately no significant reduction in CMV
infection rate was found in the acyclovir treated patients
(Table III).
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Table II Log rank analysis of time to HSV, VZV and CMV infections by treatment allocation
HSV VZV CMV
Risk period Group Obs Exp P Obs Exp P Obs Exp P
Up to 6 months AVC 5 12.07 <0.001 - 0 3.07 0.006 10 10.95 n.s.
Placebo 17 9.93 6 2.93 11 10.05
6 months+ ACV 4 2.43 0.06 6 3.69 0.05 0 0.00 n.s.
Placebo 0 1.59 2 4.31 0 0.00
Total ACV 9 14.50 0.015 6 6.76 0.34 10 10.95 n.s.
Placebo 17 11.50 8 7.24 11 10.05
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Figure 3 Cumulative probability of cytomegalovirus infection in
patients receiving acyclovir (solid line) or placebo (dotted line).
Table III CMV infection in patients according to pre-
treatment serological status in the acyclovir and placebo
treatment groups
CMV seropositive CMV seronegative
n Obs Exp O/E n Obs Exp OIE
ACV 22 8 8.362 0.96 20 2 3.555 0.56
Placebo 13 5 4.638 1.08 27 6 4.445 1.35
trial the VZV antibody determinations were done by
complement-fixation tests, which are much less sensitive than
the immunofluorescence technique used subsequently. The
majority of the patients were probably VZV seropositive pre-
transplant and so these data must be interpreted cautiously.
In view of the excess of CMV seropositive patients in the
acyclovir treated patients, an excess of CMV infection might
have been expected in this group. We considered the
possibility that the absence of such an excess indicated a
favourable therapeutic effect of acyclovir. However,
subgroup analysis does not confirm this in the numbers
available (Table III).
Survival
Although there was a highly significant difference in the
HSV and VZV infection rates in the first 6 months of
treatment, there was no overall difference in survival
between the acyclovir or placebo arms of the study and no
fatal herpes virus infections were documented.
Toxicity
Detailed prospective records were kept of serum creatinine
and urea levels, other biochemistry, liver function tests and
blood counts in each arm of the study. Time-to-event curves
were constructed for recovery of neutrophil counts to 0.5
and x 1091-1, of platelet counts to 50 and 100 x 109 1-1
and of serum creatinine to 106 (upper limit of normal), 200,
400, and 600 imolI- 1. Although renal toxicity is common in
this patient population, there was no difference between the
two arms of the trial in the proportion of patients with renal
toxicity, the severity of renal toxity or the time of onset
Acyclovir prophylaxis study
Table IV Relationship between patients antibody status pre-
transplant and incidence of active infection over one year's
observation
Infection Group No. Infections P (two-tailed)
HSV HSV +ve 54 25 <0.001
-ve 28 1
VZVa VZV +ve 39 8 n.s.
-ve 43 6
CMV CMV + ve 35 13 0.01
-ve 47 8
aSee text for influence of serological method.
Influence of pre-transplant recipient seropositivity on the
occurrence of infections
Table IV shows the relationship between infection and pre-
transplant serological status. There is a highly significant
relationship in the case of HSV where active infections were
seen almost only in patients seropositive before trans-
plantation. A less strong relationship between recipient CMV
seropositivity and CMV infection is shown. Bone marrow
CMV status was not evaluated. Varicella zoster virus sero-
logical status appeared to have no significant influence on
subsequent VZV infections. However, in the early part of the
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Figure 4 Cumulative probability of the serum creatinine
increasing to abnormal levels (> 106mm 1- 1) in patients receiving
acyclovir (solid line) or placebo (dotted line).
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Acyclovir prophylaxis study
Marrow recovery after BMT
Time to 1 x 109 neutrophils 1-
which no virological diagnosis was forthcoming. Most of
these were presumably due to cytotoxic drugs or other
infections.
Discussion
The study shows the abolition of VZV infection during the
administration of oral acyclovir. This is in keeping with a
smaller study published by Lundgren et al. (1985). The
effectiveness of oral acyclovir for this purpose confirms that
sufficient absorption occurs to achieve plasma levels capable
of inhibiting the replication of the virus. Unfortunately, once
the administration of acyclovir was stopped at 6 months,
varicella zoster virus infections recurred and there was no
overall reduction in infection rate for the year of
observation. It is possible that more prolonged
administration of acyclovir might have suppressed the virus
until the patients' immune function had recovered
sufficiently to prevent subsequent reactivations. A trial of
one year's administration of oral acyclovir is now under
0 1 2 3 4 5 6 7 8 9 10o1l l2 consideration. This study also contirms that bothintravenous and oral acyclovir can significantly reduce theMonths since transplant rate of infections with HSV after allogeneic bone marrow
---Control - 6 Month ACV transplantation. This has been previously shown by others
(Wade et al., 1984; Gluckman et al., 1983; Saral et al., 1981;
Acyclovir prophylaxis study Hann et al., 1983; Shepp et al., 1987). The incidence of HSV
infection in the treatment arm of this trial is higher than that
Time to 100 x 109 platelets 1 observed in these other studies and there is no obviousexplanation for this. The viral sensitivity to acyclovir has not
been analysed. The prompt use of 'open' acyclovir for
infections in the placebo arm appears to have avoided
clinical problems due to dissemination of HSV.
We have not demonstrated any effect against cytomegalo-
virus of this dose of acyclovir. Meyers et al. (1988) have
observed a reduction in CMV infection in patients given
larger doses of acyclovir (500 mgm -2) compared to a
concurrent, non-randomised, control group. If acyclovir has
an effect against cytomegalovirus it may only be with the
administration of these large doses and multi-centre studies
to evaluate this further are now planned.
We did not document any significant evidence of toxicity
of acyclovir in this trial. It is particularly satisfactory that no
delay in bone marrow recovery or renal toxicity was seen.
Although acyclovir is capable of suppressing HSV and
VZV and infections during the period of administration it
does not eradicate the virus. It may be valuable for patients
0 1 2 3 4 5 6 7 8 9 10 11 12 to have their infections postponed until they are medically
Months since transplant fitter when the risk of dissemination is reduced. However,fatal dissemination infection is not seen in the control arm of
---Control -6 Month ACV this trial, probably because prompt use of acyclovir when
infection is diagnosed is capable of preventing these
(a) Cumulative probability of neutrophil count manifestations. The case for the routine use of acyclovir
1 x 109 1 '- in patients receiving acyclovir (solid line) or prophylactically after allogeneic bone marrow
(dotted line); (b) Cumulative probability of platelet transplantation is therefore uncertain. Several factors must
attaining 100 x 109 1 in patients receiving acyclovir be considered. Early infection may be particularly unpleasantie) or placebo (dotted line). and can now be prevented. Without prophylaxis, there must
be very careful clinical and virological surveillance and this
has to be weighed against the inconvenience and cost of
prolonged oral administration. At present we feel that long-
m). Recovery times of neutrophils and platelets in the term routine prophylaxis is not indicated except for patients
tment arms were identical and are illustrated in with a previous history of recurrent or severe herpes virus
infection. The factors influencing this judgement may alter ifd prospective records were kept to compare the well absorbed prodrugs become available, such as desciclovir
and placebo arms for the instance of dizziness or (Selby et al., 1984), which may make sustained release
ical abnormalities. No differences were observed preparations feasible with reduced inconvenience for the
the two arms of the study. patient.
Use of open acyclovir
There was a highly significant reduction in the number of
patients requiring open acyclovir administration in the
treatment arms of the trial. The use of open acyclovir in the
treatment arm was principally associated with sore mouths
thnt uiurp i-linic-nllv eiienfo-tfil to hi- MV infpcrtion hilt for
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Flanagan Ward, Royal Marsden Hospital, Sutton. Peter Selby,
Douglas Easton and Timothy Perren are supported by programmme
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